Potential anxiolytic- And antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents

British Journal of Pharmacology

Volumn 157, Issue 5, 2009, Pages 844-853

  Braida, Daniela ^a   Capurro, Valeria ^a   Zani, Alessia ^a   Rubino, Tiziana ^b   Viganò, Daniela ^b   Parolaro, Daniela ^a,b   Sala, Mariaelvina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Benzodiazepine; Binding; Emotional response; Endocannablnoid system; K opioid receptor; Salvia divinorum; Tricyclic antidepressant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE; KAPPA OPIATE RECEPTOR; NORBINALTORPHIMINE; SALVINORIN A;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; HIPPOCAMPUS; MALE; MAZE TEST; MOOD; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

AMIDOHYDROLASES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BRAIN; CYCLOHEXANOLS; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MODELS, ANIMAL; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; PYRAZOLES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, KAPPA; SALVIA; SWIMMING;

EID: 70350166693     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00230.x     Document Type: Article

References (49)

1. Alexander SPH, Mathie A, Peters J (2008). 3rd edition. Guide to receptors and channels (GRAC). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Bambico FR, Katz N, Debonnel G, Gobbi G (2007). Cannabinoids elicit antidepressant-like behaviour and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27: 11700-11711. (Pubitemid 350006914)
3. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY (2007). Antidepressant-like effects of Mglurl and mglur5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 17: 172-179. (Pubitemid 44779190)
4. Bradford MM (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Braida D, Sala M (2000). Cannabinoid-induced working memory impairment is reversed by a second generation Cholinesterase inhibitor in rats. Neuroreport 11: 2025-2029. (Pubitemid 30429157)
6. 1-cannabinoid receptor involvement. Psychopharmacology 190: 441-448.
7. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P et at. (2008). Involvement of kappa-opioid and endocannablnoid system on salvinorin A-induced reward. Biol Psychiatry 63: 286-292.
8. Butelman ER, Harris TJ, Kreek MJ (2004). The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 172: 220-224.
9. Capasso R, Borrelli F, Capasso F, Siebert DJ, Stewart DJ, Zjawiony JK et al. (2006). The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 18: 69-75.
10. Capasso R, Borrelli F, Caseio MG, Aviello G, Huben K, Zjawiony JK et al. (2008). Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 155: 681-689.
11. Carlezon WA Jr, Beguin C, Dinieri JA, Baumann MH, Richards MR, Todtenkopf MS et al. (2006). Depressive-like effects of the kappaopioid receptor agonist salvinorin A on behaviour and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447. (Pubitemid 41832624)
12. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203. (Pubitemid 38263998)
13. Crawley JN (2000). What's wrong with my mouse? Behavioural phenotyping of transgenic and knockout mice. Wiley-Liss: New York.
14. Detke MJ, Rickels M, Lucki I (1995). Active behaviours in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121: 66-72.
15. Gobbi F, Bambico R, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. (2005). Antidepressant-like activity and modulation of brain monoaminerglc transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102: 18620-18625. (Pubitemid 43011275)
16. González D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006). Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85: 157-162. (Pubitemid 44468138)
17. 1,-specific agents. Behav Pharmacol 15: 299-304.
18. Haller VL, Stevens DL, Welch SP (2008). Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur J Pharmacol 600: 50-58.
19. Hanes KR (2001). Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 211: 634-635.
20. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C (1991). Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41: 89-125.
21. Hogg S (1996). A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 54: 21-30.
22. Holt S, Cornelli F, Costa B, Fowler CJ (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw Inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146: 467-476. (Pubitemid 41486689)
23. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81. (Pubitemid 36098263)
24. 1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 23: 9506-9518.
25. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr (2007). Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323: 838-845.
26. Kuzmin A, Madjid N, Terenius L, Ogren SO, Bakalkin G (2006). Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 31: 1928-1937. (Pubitemid 44246339)
27. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185.
28. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ (2006). Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83: 109-113.
29. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioural responses. J Neurosci 23: 5674-5683. (Pubitemid 36807845)
30. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr et al. (2003). Antidepressant-like effects of kappaopioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330. (Pubitemid 36373867)
31. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H et al. (1994). Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350: 412-438. (Pubitemid 24356007)
32. Mowry M, Mosher M, Briner W (2003). Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 35: 379-382. (Pubitemid 37237388)
33. Nestler EJ, Carlezon WA Jr (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59: 1151-1159.
34. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318: 304-311. (Pubitemid 43920770)
35. Pellow S, Chopin P, Briley M, File SE (1985). The validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167. (Pubitemid 16239568)
36. Pfeiffer A, Knepel W, Braun S, Meyer HD, Lohmann H, Brantl V (1986). Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Harm Metab Res 18: 842-848. (Pubitemid 17196588)
37. Porsolt RD, Bertin A, Jalfre M (1977). Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336. (Pubitemid 8225714)
38. Porsolt RD, Bertin A, Jalfre M (1978). Behavioural despair in rats and mice: strain differences and the effects of Imipramine. Eur J Pharmacol 51: 291-294. (Pubitemid 9208063)
39. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S (2002). Salvinorin A: a potent naturally occurring non-nitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99: 1193411939. (Pubitemid 34994502)
40. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E et al. (2008). Role in anxiety behavior of the endocannabinold system in the prefrontal cortex. Cereb Cortex 18: 1292-1301. (Pubitemid 351769783)
41. Sheffler DJ, Roth BL (2003). Salvinorin A: the 'magic mint' hallucino-gen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24: 107-109.
42. Siebert D (1994). Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43: 53-56. (Pubitemid 24186510)
43. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85: 367-370. (Pubitemid 15123115)
44. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr (2004). Effects of kappa-opioid receptor ligands on intracranial selfstimulation in rats. Psychopharmacology 172: 463-470.
45. Ukai M, Suzuki M, Mamiya T (2002). Effects of U-50,488H, a k-opioid receptor agonist, on the learned helplessness model of depression in mice. J Neural Transm 109: 1221-1225. (Pubitemid 35013722)
46. Valdes LJ, Diaz JL, Paul AG (1983). Ethnopharmacology of ska Maria Pastora (Salvia divinorum). J Ethnopharmacol 7: 287-312.
47. Wise RA, Bozarth MA (1982). Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav 17: 239-243.
48. Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H et al. (2008). Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34: 775-785.
49. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005). Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179: 551-558. (Pubitemid 40674756)